Company / Free Cash Flow
AMICUS THERAPEUTICS, INC. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$29.8M
FY2025
5-year range
-$206.4M / $29.8M
FY2021-FY2025
Trend
+179.7%
vs FY2024
Sector context
#60 of 194
Health Care
What the data says
At $30M, AMICUS THERAPEUTICS, INC.'s free cash flow ranks #60 of 194 in the Health Care sector. Free Cash Flow has increased for 7 consecutive years, from -$306M in FY2018 to $30M in FY2025.
Based on SEC 10-K filings.
$30M in FY2025.
Improved from -$77M to $30M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#60 of 194 in Health CareTop 31% of 194This company $29.8M Sector average $470.6M
▼
-93.7% below sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s free cash flow has grown for 7 consecutive years.
- In FY2025, free cash flow increased 179.7% year-over-year.
- Ranks #60 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.8M | +179.7% |
| FY2024 | -$37.4M | +51.1% |
| FY2023 | -$76.5M | +55.1% |
| FY2022 | -$170.3M | +17.5% |
| FY2021 | -$206.4M | +12.7% |
| FY2020 | -$236.5M | +12.5% |
| FY2019 | -$270.4M | +11.7% |
| FY2018 | -$306.3M | -40.3% |
| FY2017 | -$218.2M | -39.8% |
| FY2016 | -$156.1M | -48.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026